A drug patent ruling by India's Supreme Court has received worldwide attention and could signal a new role and prominence for developing nations in intellectual property law, writes Ahmed Abdel Latif of the International Centre for Trade and Sustainable Development. PhRMA President and CEO John J. Castellani has cautioned that the ruling was "the latest in a troubling pattern of decisions." The case could remain exceptional or form a pattern of developing nations taking a leadership role in IP law, Latif writes.

Related Summaries